Visualizing the Future of Presbyopia

Overview
Presbyopia is a natural result of aging, and eventually affects all individuals who reach an advanced age. This live virtual event will include discussions on the shortcomings of current treatments, clinical trial data on the emerging pharmaceutical options for the treatment of presbyopia, and patient selection for these novel therapies.Supported by an independent medical educational grant from Allergan.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the underlying mechanisms of presbyopic changes.
- Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting (PC) options.
- Differentiate among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action (MOA).
- Explain how PC drops are likely to affect categories of patients based on individual characteristics.
- Compare the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.
Accreditation
This educational activity is provided by Evolve Medical Education.
Accreditation Statement Evolve Medical Education, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement Evolve Medical Education, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers: Internet Explorer 11 for Windows Edge (recent versions; Chromium-based) for Windows Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
FACULTYFrancis S. Mah, MD Program Chair Program Moderator Director, Cornea and External Disease Co-Director, Refractive Surgery Scripps Clinic La Jolla, CA Marjan Farid, MD Professor of Ophthalmology School of Medicine Vice Chair, Ophthalmic Faculty Director, Cornea/External Disease, Cataract, and Refractive Surgery Gavin Herbert Eye Institute University of California, Irvine Irvine, CA Daniel H. Chang, MD Cataract and Refractive Surgeon Clinical Research Director Empire Eye and Laser Center Bakersfield, CA DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:
Francis S. Mah, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau:Alcon; Allergan; Bausch + Lomb; Johnson &Johnson Vision; Glaukos; Eyenovia; iView; Nevakar; Novartis; Ocular Science; and RxSight.
Marjan Farid, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bio-Tissue, CorneaGen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Orasis, and Zeiss
Daniel H. Chang, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, Omega Ophthalmics, and Mynosys. Grant/Research Support: Acufocus, Johnson & Johnson Vision, and Mynosys. Shareholder: Omega Ophthalmics.
The Evolve Medical Education staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 12/14/2020

Title

Share on ReachMD